drugset / Trial / NCT00390585

Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)

NCT00390585 ↗

Phase 4 Completed 324 enrolled German Heart Center Munich
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast medium Iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary interventions (PCI).

Timeline

Start
2006-07
Primary completion
2008-01
Completion
2008-12

Outcome

Missed primary endpoint

paper It was not significantly different between the 2 contrast groups (0.19+/-0.40 mg/dL for iodixanol and 0.21+/-0.34 mg/dL for iomeprol; P=0.53). PMID 20031753 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Iodixanol Diagnostic / imaging agent 320 unknown —
Comparator Iomeprol Diagnostic / imaging agent 350 unknown —